At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed low-grade astrocytoma
- ✓Persistent or progressive tumor after standard therapy documented by MRI within 2 weeks prior to study entry
- ✓Tumor at least 5 mm in size
- ✓Age 6 months to 17 years
- ✕Prior Antineoplaston therapy
- ✕Severe heart disease, uncontrolled hypertension, history of congestive heart failure, or cardiovascular conditions that contraindicate high-dose sodium
- ✕Severe lung disease
- ✕History of renal conditions that contraindicate high-dose sodium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade Astrocytoma
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Low Grade Astrocytomas. Completed, enrolled 11 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for children with low grade astrocytomas that have not responded to standard therapy provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with low grade astrocytomas that have not responded to standard therapy PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) with low grade astrocytomas that has not responded to standard therapy.
Study Details
Timeline
Interventions
Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).